全部文献期刊会议图书|学者科研项目
中外文文献  中文文献  外文文献
作者:F. De Felice , C. Marchetti , I. Palaia ...
来源:[J].Critical Reviews in Oncology / Hematology(IF 4.637), 2018, Vol.129, pp.40-43Elsevier
摘要:... In recent years, researches have investigated immune check-point inhibitors in hopes of determining improved response to therapy with prolongation of survival.(#br)We reviewed the published literature and conference proceedings and presented pivotal trials supporting immune check-point...
作者:F. De Felice , N. Pranno , F. Marampon ...
来源:[J].Critical Reviews in Oncology / Hematology(IF 4.637), 2019, Vol.138, pp.60-69Elsevier
摘要:... During this decade, different research groups have explored immune check-point inhibitors role in order to improve response to therapy and subsequently prolong survival rate. The aim of this review was to analyze published literature to support immune check-point inhibitors u...
作者:Francesca Felice , Claudia Marchetti , Vincenzo Tombolini ...
来源:[J].International Journal of Clinical Oncology(IF 1.727), 2019, Vol.24 (8), pp.910-916Springer
摘要:... Based on the new EC molecular classification, we focused on the impact of immune check-point inhibitors.(#br) Methods(#br)Pivotal trials, published literature, and conference proceedings were reviewed. PubMed and Scopus databases were searched to select English-language artic...
作者:Ludovic Fournel , Zherui Wu , Nicolas Stadler ...
来源:[J].Cancer Letters(IF 4.258), 2019, Vol.464, pp.5-14Elsevier
摘要:Abstract(#br)The number of clinical protocols testing combined therapies including immune check-point inhibitors and platinum salts is currently increasing in lung cancer treatment, however preclinical studies and rationale are often lacking. Here, we evaluated the impact of ...
作者:Elizabeth Dudnik , Nir Peled , Hovav Nechushtan ...
来源:[J].Journal of Thoracic Oncology(IF 4.473), 2018Elsevier
摘要:Abstract(#br)Introduction(#br)The efficacy of immune checkpoint inhibitors (ICPi) in BRAF mutant NSCLC is unknown.(#br)Methods(#br)Multi-institutional retrospective chart review identified 39 patients with BRAF mutant NSCLC. The patients were divided into two groups: V600E (gr...
作者:Luigia Stefania Stucci , Stella D'Oronzo , Marco Tucci ...
来源:[J].Cancer Treatment Reviews(IF 6.024), 2018, Vol.69, pp.21-28Elsevier
摘要:...(#br)However, recent evidence suggests that vitamin D exerts both anti-proliferative effects on tumor cells and immune-modulating activities, that have been widely explored in auto-immune disorders. On the one hand, vitamin D has been shown to inhibit T-helper17 lymphocytes, n...
作者:Genova , Rossi , Rijavec ...
来源:[J].Expert Opinion on Drug Safety(IF 2.621), 2017, Vol.16 (5), pp.573-585Taylor & Francis
摘要:ABSTRACT(#br)Introduction(#br): Immune check-point inhibitors are now employed as single-agents in current practice for the treatment of advanced non-small cell lung cancer (NSCLC), while combinations of different inhibitors are being evaluated in clinical trials. Although the sa...
作者:Shira Sherman , Ofer Rotem , Tzippy Shochat ...
来源:[J].Lung Cancer(IF 3.392), 2020
摘要:Abstract(#br)Objectives(#br)Little is known regarding the ICPi efficacy in LCNEC. We explored the efficacy and safety of ICPi in LCNEC and assessed its impact on OS.(#br)Materials and methods(#br)Thirty-seven consecutive patients with advanced LCNEC were selected from the Davidof...
作者:Katsuhisa Sekido , Kei Tomihara , Hidetake Tachinami ...
来源:[J].Oral Oncology(IF 2.695), 2019, Vol.99
摘要:Abstract(#br)Objectives(#br)Aging has been suggested to be associated with immune dysregulation. An understanding of alterations in the host immunity with advancing age is, therefore, important for designing immune therapy for elderly cancer patients. In this context, not much is...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×